Home » Authors » Rainer B. Langen

Articles by Rainer B. Langen

Schering To Purchase Collateral For $140M In Stock Exchange

March 27, 2002

By Rainer B. Langen

Paion, Millennium Cooperate In Development Of MLN519

March 20, 2002

By Rainer B. Langen

Co.don Starts Phase III Trials Of DISC In Herniated Discs

March 20, 2002

By Rainer B. Langen

LION Streamlining Operations, Eliminating About 80 Positions

Feb. 20, 2002

By Rainer B. Langen

German Officials Compromise In Embryonic Stem Cell Debate

Feb. 6, 2002

By Rainer B. Langen

BioVisioN Raises EUR15M To Progress Programs In Peptides

Feb. 6, 2002

By Rainer B. Langen

Biogen Paying Schering $20M Or More Over MS Drug Patents

Jan. 30, 2002

By Rainer B. Langen

Merck KGaA Says Development Of ImClone Drug Stays On Track

Jan. 25, 2002

By Rainer B. Langen

Estonia Expects Gene Project To Help Health, Economy; Latvia Next

Jan. 23, 2002

By Rainer B. Langen

LION Acquiring NetGenics In Stock Deal Valued At US$17M

Jan. 23, 2002

By Rainer B. Langen

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...